INTRODUCTION
============

Insulin biosynthesis is initiated when preproinsulin is translocated into the endoplasmic reticulum (ER) ([@B33]) and its signal sequence is cleaved to generate proinsulin. Oxidative folding of proinsulin ensues ([@B26]), characterized by formation of three highly conserved disulfide bonds (denoted as B7-A7, B19-A20, and A6-A11). Properly folded proinsulin then exits the ER, is transported to the Golgi, and is delivered to secretory granules, where pro--hormone convertases excise the C-peptide, with B and A chains of mature insulin remaining attached via B7-A7 and B19-A20 interchain disulfide bonds.

Recently a subset of human insulin gene mutations has been discovered to cause an autosomal-dominant syndrome that we call mutant *INS* gene--induced diabetes of youth (MIDY; [@B35]; [@B24]; [@B40]): insulin-deficient diabetes without islet autoantibodies. MIDY is a protein-misfolding disease, and most MIDY proinsulin mutants misfold within the ER, causing permanent neonatal or later-onset diabetes, depending upon the particular mutation. Among these, the most-studied MIDY mutant is *Akita* proinsulin: substitution at the A7 cysteine causes severe early-onset diabetes in both humans and *Akita* mice.

MIDY mutants fail to be transported from the ER to the Golgi complex. Moreover, MIDY mutants impair wild-type (WT) proinsulin exit from the ER, thereby limiting WT insulin production, provoking increased blood glucose excursions, and stimulating expression of even more proinsulin (both mutant and WT), which remains entrapped within the ER ([@B25]; [@B40]). This triggers ER stress that may ultimately result in β-cell death.

Eliminating buildup of mutant proinsulin in the ER might restore β-cell function and survival. This possibility motivates us to investigate cellular mechanisms of degradation of misfolded proinsulin. One such mechanism is the ER-associated degradation (ERAD) pathway ([@B38]; [@B31]). In ERAD, a misfolded ER substrate must first be identified by ER lumenal components and then delivered across (retrotranslocated) to the cytosolic side of the ER membrane for ubiquitination, with the assistance of ERAD membrane components ([@B8]; [@B34]). Finally, the ubiquitinated substrate is extracted from the ER membrane into the cytosol for delivery to proteasomes for degradation ([@B43]).

There is reason to suspect that MIDY mutants may use the ERAD pathway ([@B1]; [@B16]; [@B36]), although how misfolded proinsulin in the ER lumen is recognized and primed for retrotranslocation remains unknown. Here we establish that canonical ERAD membrane components, including the E3 ubiquitin ligase Hrd1, its membrane-binding partner Sel1L, and cytosolic p97, help to conduct *Akita* proinsulin from the ER lumen to the cytosol. Strikingly, we find that protein disulfide isomerase (PDI), a profolding enzyme known to drive oxidation of disulfide bonds ([@B17]; [@B3]), instead exhibits a novel interaction with misfolded proinsulin to exert a prodegradative role that includes reducing proinsulin disulfide bonds. Our findings provide a framework for rational therapeutic approaches to preventing and treating diabetes provoked by proinsulin misfolding.

RESULTS
=======

The Hrd1-Sel1L complex promotes ERAD of *Akita* proinsulin
----------------------------------------------------------

To determine whether *Akita* proinsulin is degraded by ERAD, we first evaluated whether Hrd1, the multitransmembrane E3 ubiquitin ligase that is also proposed to function as the retrotranslocon ([@B8]; [@B34]), controls the fate of transfected (Myc-tagged) *Akita* proinsulin. Using cycloheximide chase in 293T cells (and in β-cells; see later discussion), we found that Hrd1 knockdown markedly impaired degradation of *Akita* proinsulin ([Figure 1A](#F1){ref-type="fig"}; quantified in [Figure 1B](#F1){ref-type="fig"}). Of importance, depleting Hrd1 (or any other protein described in this study) did not trigger massive ER stress, as XBP1 remained largely unspliced under these conditions (Supplemental Figure S1A). Our analyses also demonstrated that overexpressing enzymatically inactive, dominant-negative Hrd1-C291A ([@B4]) potently stabilized *Akita* proinsulin ([Figure 1C](#F1){ref-type="fig"}, top). A smaller degree of inhibition of degradation of *Akita* proinsulin was also observed upon WT Hrd1-Myc overexpression (this is likely due to perturbation of the stoichiometric ratio of Hrd1 to its natural binding partners, in this way decreasing the efficiency of functional Hrd1-associated complexes). Overexpression of WT, mutant Hrd1, or any other construct in this study also did not provoke enhanced XBP1 splicing (Supplemental Figure S1B). Together the results in [Figure 1, A--C](#F1){ref-type="fig"}, indicate that Hrd1 participates in the degradation of *Akita* proinsulin. Next we asked whether Sel1L also promotes ERAD of *Akita* proinsulin. Sel1L is a membrane protein that serves as a scaffold to engage ERAD lumenal components ([@B19]; [@B27]; [@B41]), interacts with Hrd1 ([@B28]), and recruits client substrates to Hrd1 ([@B5]; [@B32]). Using a similar cycloheximide-chase protocol, we found that Sel1L knockdown also impaired *Akita* ERAD ([Figure 1D](#F1){ref-type="fig"}; quantified in [Figure 1B](#F1){ref-type="fig"}), strongly implicating the Hrd1-Sel1L membrane complex in the degradation of *Akita* proinsulin.

![The Hrd1-Sel1L complex promotes ERAD of *Akita.* (A) 293T cells expressing *Akita*-Myc were transfected with a scrambled or Hrd1-specific siRNA. Cells were then treated with cycloheximide for the indicated time and harvested, and the resulting WCE was analyzed by using the indicated antibodies. (B) The *Akita* band intensity in A and D was quantified with ImageJ (National Institutes of Health, Bethesda, MD). Data represent mean ± SD of at least three independent experiments. (C) As in A, except that cells were transfected with GFP-FLAG, WT Hrd1-Myc, or C291A Hrd1-Myc construct. (D) As in A, except cells were transfected with a siRNA against Sel1L. The black vertical line indicates that an intervening lane from the same immunoblot has been spliced out.](3413fig1){#F1}

Because *Akita* appears to use the classic ERAD pathway in which the Hrd1-Sel1L complex serves as the core membrane component, we asked whether expressing WT proinsulin might affect ERAD of *Akita*, as patients with MIDY harbor one WT copy of the proinsulin gene. Indeed, coexpressing superfolder green fluorescent protein--tagged WT proinsulin (SfGFP-WT proinsulin, which largely behaves as WT proinsulin; [@B15]) significantly impaired degradation of Myc-tagged *Akita* (Supplemental Figure S1C, top). This result suggests that the established interaction between WT proinsulin and *Akita* ([@B25]) can functionally disrupt degradation of *Akita*, potentially exacerbating ER stress, which contributes to MIDY.

p97 facilitates *Akita* degradation
-----------------------------------

Because Hrd1 orients its catalytic E3 ligase domain on the cytosolic surface of the ER membrane, retrotranslocated substrates become available for ubiquitination, and the ubiquitinated substrates are then extracted into the cytosol---in most cases by the cytosolic p97 ATPase ([@B43])---before being degraded by cytosolic proteasomes. To assess whether p97 participates in ERAD of *Akita* proinsulin, we overexpressed a histidine (His)-tagged WT or ATPase-defective dominant-negative version of p97 (QQ-p97). Whereas WT p97 was largely without effect, overexpression of QQ p97-His markedly stabilized *Akita* proinsulin ([Figure 2A](#F2){ref-type="fig"}; quantified in [Figure 2B](#F2){ref-type="fig"}), implicating p97 in the extraction of *Akita* proinsulin from the ER membrane to the cytosol.

![p97 facilitates *Akita* degradation. (A) As in [Figure 1C](#F1){ref-type="fig"}, except that 293T cells were transfected with WT p97-His or QQ p97-His. (B) As in [Figure 1B](#F1){ref-type="fig"}, except that the *Akita* band intensity in A is quantified. (C) 293T cells expressing *Akita*-Myc or not were transfected with an empty vector or QQ p97-His as indicated. Cells were lysed in a RIPA buffer and *Akita* immunoprecipitated from the resulting WCE using a Myc antibody. The precipitated material was subjected to SDS--PAGE and immunoblotted with the indicated antibodies. The WCE was also immunoblotted.](3413fig2){#F2}

Because p97 binds to ubiquitinated substrates, blocking *Akita* proinsulin extraction into the cytosol should cause *Akita* proinsulin to accumulate as an ubiquitinated species. To test this, we cotransfected cells to express *Akita* proinsulin and QQ p97-His. When Myc-tagged *Akita* proinsulin was immunoprecipitated ([Figure 2C](#F2){ref-type="fig"}, second from top), the polyubiquitinated species accumulated only in cells expressing QQ p97-His ([Figure 2C](#F2){ref-type="fig"}, top). This finding is consistent with the idea that p97 extracts ubiquitinated *Akita* proinsulin from the ER membrane and supports that the classic Hrd1/Sel1L-p97 pathway promotes ERAD of *Akita* proinsulin.

PDI promotes *Akita* degradation
--------------------------------

One major impediment to ERAD is the presence of disulfide bonds that hold the substrate in a plicated conformation believed to be incompatible with retrotranslocation. Because *Akita* proinsulin still harbors five cysteine residues in an aberrant disulfide configuration ([@B21]; [@B25], [@B23]) that is unknown, enzymatic reduction of disulfide bonds is likely important for its retrotranslocation. The major ER-resident oxidoreductase is PDI, which is believed to promote oxidative folding of many newly synthesized secretory proteins ([@B17]; [@B3]). However, PDI does not appear to facilitate oxidative folding of proinsulin in the ER of pancreatic β-cells ([@B29]) and in fact has been implicated in retrotranslocation of certain ERAD substrates and a bacterial toxin ([@B13]; [@B12]). Indeed, we found that in cells in which PDI was knocked down for 3 d, *Akita* proinsulin was robustly stabilized ([Figure 3A](#F3){ref-type="fig"}; quantified in [Figure 3B](#F3){ref-type="fig"}). A similar effect on *Akita* degradation was observed when PDI was knocked down for only 2 d (Supplemental Figure S1D). When a small interfering RNA (siRNA)--resistant PDI construct was expressed in PDI-knockdown cells, degradation of *Akita* proinsulin was largely restored ([Figure 3C](#F3){ref-type="fig"}; quantified in [Figure 3B](#F3){ref-type="fig"}). However, knockdown of ERp57 ([Figure 3D](#F3){ref-type="fig"}) or ERdj5 ([Figure 3E](#F3){ref-type="fig"}), ER-resident oxidoreductases ([@B2]; [@B39]), did not significantly affect ERAD of *Akita* proinsulin (quantified in [Figure 3B](#F3){ref-type="fig"}). These data strongly suggest that ERAD of *Akita* proinsulin is specifically targeted by PDI.

![PDI exerts a key role in regulating *Akita* degradation. (A) As in [Figure 1A](#F1){ref-type="fig"}, except that 293T cells were transfected with a PDI-specific siRNA for 3 d. (B) As in [Figure 1C](#F1){ref-type="fig"}, except that the *Akita* band intensity in A and C--E are quantified. (C) As in A, except where indicated cells transfected with a PDI-specific siRNA for 3 d were cotransfected with a PDI construct resistant to the PDI-specific siRNA. (D) As in A, except hat cells were transfected with an ERp57-specific siRNA. (E) As in A, except that cells were transfected with an ERdj5-specific siRNA. (F) 293T cells expressing either a control or PDI-specific siRNA were cotransfected with ΔCys-Myc and treated or not with MG132 as indicated. (G) Cells expressing WT proinsulin-Myc or ΔCys-Myc were treated with DTT (10 μM) in the presence of MG132 and the WCE analyzed as in F. (H) 293T cells expressing the indicated Myc-tagged mutant proinsulins were cotransfected with PDI C56A-FLAG. The cells were lysed and immunoprecipitated with M2 FLAG antibody-conjugated beads, analyzed by reducing SDS--PAGE, and immunoblotted using the appropriate antibodies. The WCE was also directly immunoblotted with anti-Myc or anti-FLAG antibodies. pTarget was the plasmid used as a control for the mutant proinsulin constructs.](3413fig3){#F3}

PDI can function as both an ER molecular chaperone and an ER oxidoreductase ([@B7]). To understand the predominant role of PDI in the ERAD of *Akita* proinsulin, we tested whether knockdown of PDI affected degradation of a proinsulin construct lacking all Cys residues (ΔCys-Myc; [@B23]), which is detected intracellularly in the presence, but not the absence, of MG132 treatment ([Figure 3F](#F3){ref-type="fig"}). Of importance, silencing of PDI did not augment the steady-state level of ΔCys-Myc ([Figure 3F](#F3){ref-type="fig"}), suggesting that the mechanism by which PDI facilitates retrotranslocation of *Akita* proinsulin likely involves interaction with one or more of its cysteine residues. A low level of a slower-migrating species ([Figure 3F](#F3){ref-type="fig"}, asterisk) that appeared in the PDI-depleted cells may represent a different folded conformation of this artificial mutant proinsulin that persists even under SDS--PAGE, consistent with PDI being a chaperone that unfolds ERAD substrates during retrotranslocation ([@B13]). Of interest, treating cells with the reducing agent dithiothreitol (DTT) did not alter ΔCys-Myc's steady-state level but did for WT proinsulin-Myc ([Figure 3G](#F3){ref-type="fig"}), suggesting that degradation of the cysteine-less proinsulin mutant is unaffected by changing the cellular redox state.

PDI interacts with, and acts as a reductase for, *Akita* proinsulin
-------------------------------------------------------------------

To determine whether initiation of ERAD of *Akita* proinsulin involves a direct interaction with PDI, we exploited so-called PDI trap mutants, in which a CXXC thioredoxin motif (where C = cysteine and X = any amino acid) is mutated to CXXA. When functioning as a reductase, the first cysteine thiol of the CXXC motif attacks a disulfide bond in the substrate to form a mixed-disulfide intermediate that is rapidly broken by intradomain disulfide pairing with the second CXXC cysteine thiol. These steps reduce the substrate disulfide bond while internally oxidizing the thioredoxin motif. However, CXXA trap mutants can only cross-link with the substrate and cannot form the intradomain disulfide pair, thereby "trapping" mixed disulfide-bonded adducts between PDI and its substrates. Because PDI possesses two thioredoxin domains, we used two (FLAG-tagged) trap mutants: PDI C56A, to create the first CXXA, and PDI C400A, to create the second CXXA. When coexpressed with *Akita* proinsulin, we found that precipitation of either PDI trap mutant recovered disulfide-bonded adducts engaging both PDI and *Akita* under nonreducing conditions ([Figure 4A](#F4){ref-type="fig"}, top). As a control, precipitating WT PDI did not recover any disulfide-bonded adduct with *Akita* (Supplemental Figure S2A, compare lane 2 to lane 4). One of the main adducts recovered by precipitating PDI C56A had a molecular mass of ∼69 kDa ([Figure 4A](#F4){ref-type="fig"}, asterisk) which corresponds precisely to the cumulative molecular masses of one PDI (59 kDa) plus one proinsulin (∼10 kDa), strongly suggesting a direct disulfide bond rather than binding via intermediary proteins. Of interest, precipitation of PDI C400A recovered an adduct of ∼79 kDa ([Figure 4A](#F4){ref-type="fig"}, triple asterisks), likely representing one PDI molecule plus an *Akita* dimer. Other proinsulin-containing PDI adducts ([Figure 4A](#F4){ref-type="fig"}, double and quadruple asterisks) were also recovered. By contrast, neither of two different ERp57 trap mutants nor three distinct ERp72 trap mutants captured *Akita* proinsulin (Supplemental Figure S2B), strongly suggesting that PDI specifically engages *Akita* proinsulin.

![PDI acts as a reductase against *Akita.* (A) 293T cells expressing *Akita* were transfected with or without PDI C56A-FLAG or PDI C400A-FLAG. Tagged PDI proteins were immunoprecipitated from the resulting WCE using a FLAG antibody. The precipitated material was subjected to nonreducing or reducing SDS--PAGE as indicated and immunoblotted using the appropriate antibodies. The WCE was also immunoblotted with a Myc antibody. (B) 293T cells expressing *Akita* and transfected with either a scrambled or PDI-specific siRNA were treated with or without MG132. The resulting WCE was subjected to nonreducing or reducing SDS--PAGE as indicated and immunoblotted using the indicated antibodies. The black vertical line indicates that an intervening lane from the same immunoblot has been spliced out. (C) Lanes 1--4, WCE in B was treated with or without DTT, layered over a 20% sucrose cushion, and centrifuged. The top and bottom fractions were separated and subjected to SDS--PAGE, followed by immunoblotting using a Myc antibody. Lanes 5 and 6, WCE was subjected to SDS--PAGE, followed by immunoblotting using the indicated antibodies. (D) His-tagged PDI purified from bacteria is shown in the Coomassie gel. Immunoprecipitated *Akita*-Myc from PDI-knockdown cells was incubated with PDI or IAA-modified PDI in the presence of 1 mM GSH and 1 mM GSSG, and the samples were subjected to nonreducing SDS--PAGE, followed by immunoblotting with a Myc antibody. Bottom graph, the intensity level of *Akita* dimer and trimer was quantified by ImageJ. Data represent the mean ± SD of three independent experiments. The black vertical line indicates that an intervening lane from the same immunoblot has been spliced out. (E) Cells expressing *Akita* transfected with a scrambled or Hrd1-specific siRNA were cotransfected with either PDI C56A-FLAG or PDI C400A-FLAG. The ability of tagged PDI protein to interact with *Akita* was analyzed as in A.](3413fig4){#F4}

We also found that the steady-state level of *Akita* proinsulin was higher in cells expressing PDI C56A than with other trap mutants (Supplemental Figure S2B, fourth panel), suggesting that such trapping inhibits ERAD of *Akita* proinsulin. Indeed, cycloheximide-chase experiments confirmed that expression of PDI-C56A and PDI-C400A stabilized *Akita* proinsulin in comparison to expressing ERp57-C60A or P5 C58A (Supplemental Figure S2C, top), where P5 represents yet another PDI family member. These analyses provide independent evidence that PDI specifically plays a functional role in targeting *Akita* proinsulin for ERAD.

Because *Akita* proinsulin lacks a cysteine at position A7, the Cys-B7 lacks its natural partner for disulfide bonding. Although this might render Cys-B7 especially available for cross-linking with PDI, proinsulin misfolding might involve a variety of disulfide mispairings, making other Cys residues more available for adduct formation with PDI. To simplify our analysis, we constructed a family of proinsulin mutants each bearing only a single Cys residue. To our surprise, when coexpressed with the PDI-C56A trap mutant, two of the six single-Cys proinsulin mutants consistently coprecipitated to a greater degree with PDI: a proinsulin construct that harbors only the B19 Cys residue (Keep B19), and Keep A11 ([Figure 3H](#F3){ref-type="fig"}; quantified in Supplemental Figure S3A). However, even when Cys-B7 was the only available unpaired cysteine, the Keep B7 mutant did not preferentially interact with overexpressed PDI trap mutant ([Figure 3H](#F3){ref-type="fig"}; quantified in Supplemental Figure S3A). Similarly, when the various proinsulin mutants were precipitated (with anti-myc), Keep B7 consistently coprecipitated less PDI C56A-FLAG than did Keep B19 or Keep A11 (Supplemental Figure S3B). (Curiously, Keep A20 was also able to coprecipitate PDI trap mutant more efficiently than others, suggesting that A20 is also a reactive cysteine, although association of Keep A20 with PDI trap might affect epitope exposure during immunoprecipitation with anti-FLAG.) Together these coprecipitation results support that even when freely available, the proinsulin B7 cysteine is disfavored from forming a disulfide bond with PDI; thus it is more likely that a complex pattern of intramolecular disulfide mispairing within *Akita* proinsulin accounts for the robust formation of *Akita* proinsulin adducts with PDI ([Figure 4A](#F4){ref-type="fig"}).

We then examined the status of *Akita* in cells with PDI knockdown. When evaluated by nonreducing SDS--PAGE, *Akita* proinsulin in control cells formed high--molecular weight (MW) protein complexes and additionally migrated as a disulfide-bonded dimer and trimer ([Figure 4B](#F4){ref-type="fig"}, top, lane 1). In PDI-knockdown cells (lane 2), the dimer and trimer disappeared and likely entered the high-MW complex. The *Akita* monomer was revealed when the samples were subjected to reducing SDS--PAGE, with the *Akita* level being higher in PDI-depleted cells ([Figure 4B](#F4){ref-type="fig"}, second from top, lanes 1 and 2). Addition of the proteasome inhibitor MG132 did not restore loss of the *Akita* dimer or trimer observed by nonreducing SDS--PAGE in PDI-depleted cells ([Figure 4B](#F4){ref-type="fig"}, top, compare lanes 4 and 3), although the steady-state level of low-MW *Akita* did increase in the MG132-treated sample as expected ([Figure 4B](#F4){ref-type="fig"}, top, compare lane 3 with lane 1). Whereas incubation with the autophagy inhibitor LY294002 ([@B6]) did enhance the steady-state level of *Akita* in control cells (Supplemental Figure S4, compare lane 3 to lane 1), this inhibitor clearly did not restore the loss of *Akita* dimer or trimer in PDI-knockdown cells (Supplemental Figure S4, top, compare lanes 4 and 3). These results suggest that autophagy is unlikely to be responsible for the disappearance of *Akita* dimer or trimer when PDI is depleted, although this process may contribute to quality control of *Akita* in control cells. Thus the data are consistent with the idea that disappearance of dimeric and trimeric *Akita* in PDI-depleted cells reflects a loss of proinsulin reductase activity rather than ERAD or ER-dependent autophagy of dimeric and trimeric *Akita* proinsulin, suggesting that enzymatically active PDI helps to limit *Akita* proinsulin from becoming engaged in high-MW disulfide-linked complexes.

As yet another independent approach, we layered cell extracts expressing *Akita* proinsulin over a 20% sucrose cushion and centrifuged, generating bottom and top fractions. The top fraction harbors lower-MW species, likely dimeric and monomeric species of *Akita* proinsulin ([Figure 4C](#F4){ref-type="fig"}, top, lane 1), whereas the bottom fraction ([Figure 4C](#F4){ref-type="fig"}, top, lane 2) contains *Akita* proinsulin predominantly in high-MW complexes whose sizes are heterogeneous and appear to be larger than ∼55 kDa. In control cells, a small portion of *Akita* proinsulin was recovered in the top fraction, with most detected at bottom ([Figure 4C](#F4){ref-type="fig"}, top, lanes 1 and 2) whereas in PDI-knockdown cells, *Akita* proinsulin in the top fraction was eliminated (lanes 3 and 4). Of importance, when DTT was added to cell extracts before fractionation, even the PDI-knockdown cells yielded recovery of *Akita* proinsulin in the top fraction ([Figure 4C](#F4){ref-type="fig"}, second from top), mimicking the effect of PDI. In PDI-depleted cells, the combined level of *Akita* in top plus bottom fractions of DTT-treated samples is similar to the *Akita* level found in the bottom fraction only in non--DTT-treated samples ([Figure 4C](#F4){ref-type="fig"}, compare second from top and top, lanes 3 and 4). As expected, DTT reduced *Akita* in cell extracts derived from PDI-depleted cells, generating *Akita* monomer and dimer (Supplemental Figure S5). However, a significant fraction of *Akita* proinsulin remained in high-MW complexes even after reduction by DTT ([Figure 4C](#F4){ref-type="fig"}, bottom, lane 4), presumably due to noncovalent associations with each other or with other cellular proteins. This is consistent with a report suggesting that *Akita* engages in both covalent and noncovalent interactions to remain in the high-MW complexes ([@B44]). Our data thus strongly suggest that the inability to partition to the top fraction after PDI knockdown is due to a lack of reducing power for *Akita* proinsulin in the ER, supporting the notion that PDI acts as a reductase for *Akita* proinsulin. To assess whether PDI can reduce *Akita* in vitro, we used a modified protocol from the cell-based assay. *Akita* was first isolated from PDI-depleted cells by immunoprecipitation, followed by elution of the bound material using SDS and then dialysis to remove the detergent. Isolated *Akita* was subsequently incubated with bacterially purified PDI ([Figure 4D](#F4){ref-type="fig"}, lane 1) or, as a negative control, PDI alkylated with iodoacetamide (IAA; IAA-PDI), which should not reduce substrates, because its active cysteines are blocked. When this experiment was performed under a condition that mimics the ER redox environment (1 mM reduced glutathione \[GSH\] and 1 mM oxidized glutathione \[GSSG\]; [@B20]), PDI but not IAA-PDI induced formation of *Akita* dimer and trimer ([Figure 4D](#F4){ref-type="fig"}, lanes 2 and 3; the dimer and trimer levels are quantified in the bottom graph), indicating that PDI uses its catalytic cysteines to reduce *Akita*. Note that *Akita* migrated slightly differently in this experiment ([Figure 4D](#F4){ref-type="fig"}) compared with the cell-based assay ([Figure 4B](#F4){ref-type="fig"}), possibly due to the harsh conditions used to isolate *Akita* in the in vitro assay. Nonetheless, these findings support the idea that PDI directly reduces *Akita* present in high-MW disulfide-bonded complexes to generate lower-MW species.

We previously reported that a subset of PDI localizes to the lumenal side of the Hrd1 membrane complex ([@B4]), which may allow this subset of PDI molecules to reduce ERAD substrates more efficiently. To test this, we examined the extent to which PDI trap mutants can capture *Akita* proinsulin when Hrd1 expression is silenced. Indeed, upon Hrd1 knockdown, the trapping of *Akita* proinsulin by PDI-C56A and PDI-C400A declined ([Figure 4E](#F4){ref-type="fig"}, top). Thus Hrd1 availability enhances the efficiency of PDI in engaging *Akita* to reduce proinsulin disulfide bonds before retrotranslocation.

PDI, Hrd1, and p97 promote ERAD of *Akita* in pancreatic β-cells
----------------------------------------------------------------

We next explored the roles of PDI, Hrd1, and p97 in the ERAD of *Akita* proinsulin in the INS-1 832/13 pancreatic β-cell line. Similar to results observed in 293T cells (Supplemental Figure S2C), expressing the PDI trap mutants in β-cells slowed degradation of *Akita* proinsulin compared with controls (GFP-FLAG, [Figure 5A](#F5){ref-type="fig"}, top; the *Akita* band intensity is quantified in the graph at right). In addition, in INS-1 832/13 cells, *Akita* proinsulin was robustly stabilized by dominant-negative Hrd1-C291A but more modestly by WT Hrd1 ([Figure 5B](#F5){ref-type="fig"}, top; the *Akita* band intensity is quantified in the graph at right). Finally, expressing QQ p97 potently inhibited *Akita* degradation ([Figure 5C](#F5){ref-type="fig"}, top; the *Akita* band intensity is quantified in the graph at right). Together these findings indicate that, as in 293T cells, the role of the PDI-Hrd1-p97 axis in the ERAD of *Akita* proinsulin is indeed maintained within the context of pancreatic β-cells.

![PDI, Hrd1, and p97 promote ERAD of *Akita* in pancreatic β-cells. (A) As in Supplemental Figure S2C, except that rat pancreatic INS-1 832/13 β-cells were used and GFP-FLAG was expressed instead of ERp57 C60A-FLAG. The *Akita* band intensity is quantified as in [Figure 1B](#F1){ref-type="fig"}. (B) As in [Figure 1C](#F1){ref-type="fig"}, except that the experiment was performed in INS-1 832/13 β-cells and GFP-FLAG was transfected instead of vector. The *Akita* band intensity is quantified as in [Figure 1B](#F1){ref-type="fig"}. (C) As in [Figure 2A](#F2){ref-type="fig"}, except that the experiment was performed in INS-1 832/13 β-cells and GFP-FLAG was transfected instead of vector. The *Akita* band intensity is quantified as in [Figure 1B](#F1){ref-type="fig"}.](3413fig5){#F5}

DISCUSSION
==========

We propose the following model for cellular disposal of *Akita* mutant proinsulin ([Figure 6](#F6){ref-type="fig"}): disulfide bonds engaged by *Akita* proinsulin, including intermolecular disulfide bonds, are reduced by PDI (step 1), whereupon *Akita* proinsulin retrotranslocates across the ER membrane via the Hrd1/Sel1L membrane complex (indeed, Hrd1 availability enhances PDI engagement of *Akita* proinsulin; step 2). Consistent with the known enzymatic activity of Hrd1, *Akita* proinsulin becomes polyubiquitinated upon arrival at the cytosolic side of the ER membrane (step 3) before extraction into the cytosol by p97, delivering *Akita* proinsulin to cytosolic proteasomes (step 4).

![Model depicting ERAD of *Akita*. To dispose of *Akita* via the ERAD pathway, PDI reduces the disulfide bonds in this mutant proinsulin to initiate its retrotranslocation into the cytosol (step 1). The precise pairing of disulfide bonds in *Akita* proinsulin is not known. In the second step, *Akita* retrotranslocates across the ER membrane by using the Hrd1/Sel1L membrane complex (step 2). Once it is presented to the cytosol, *Akita* becomes polyubiquitinated using Hrd1's catalytic activity (step 3). In the final step, p97 propels polyubiquitinated *Akita* into the cytosol, targeting it to the proteasome for degradation (step 4).](3413fig6){#F6}

Degradation of *Akita* proinsulin engages key elements of the classic ERAD pathway
----------------------------------------------------------------------------------

Classic ERAD involves the Hrd1-Sel1L membrane complex and the cytosolic p97 ATPase ([@B38]; [@B31]). The core component is the six-transmembrane-spanning Hrd1 ([@B22]), which associates with numerous adaptor proteins. Hrd1 is believed to serve, first, as the physical conduit for transfer of client substrates from the ER lumen to the cytosol ([@B8]; [@B34]) and, second, as the major E3 ligase that ubiquitinates ERAD substrates upon arrival at the cytosolic face of the ER membrane ([@B9]). Using cycloheximide chase in conjunction with selective siRNA-mediated knockdown of Hrd1, we find that inhibiting Hrd1 function robustly blocks the degradation of *Akita* proinsulin, increasing its steady-state level ([Figure 1, A](#F1){ref-type="fig"} and B). We also find that overexpression of enzymatically inactive Hrd1 (or, to a much lesser extent, WT Hrd1) similarly produces dominant-negative inhibition of *Akita* proinsulin degradation ([Figure 1C](#F1){ref-type="fig"}). The dominant effects of recombinant Hrd1 are believed to arise by competing for natural Hrd1 binding partners, thereby impairing the proper stoichiometry and function of Hrd1-associated protein complexes. Although the results of our WT Hrd1 overexpression experiments differ slightly from those reported previously ([@B1]), our conclusions are entirely concordant with the idea that the Hrd1 E3 ligase is involved in ERAD of *Akita* proinsulin, ubiquitinating the substrate when it emerges on the cytosolic side of the ER membrane.

Moreover, our findings demonstrate that Sel1L, a membrane binding partner of Hrd1, also participates in ERAD of *Akita* proinsulin ([Figure 1, B and D](#F1){ref-type="fig"}). Yet another Hrd1 interactor, Herp, was also reported to modestly increase the steady-state level of *Akita* proinsulin, suggesting that Herp may also be involved in ERAD of this substrate ([@B16]). The findings with both Herp and Sel1L support our contention that Hrd1 and its interacting partners guide ER-to-cytosol retrotranslocation of misfolded proinsulin.

On presentation on the cytosolic side of the ER membrane, polyubiquitinated ERAD substrates encounter the cytosolic p97 ATPase, which (in conjunction with its binding partners, including Ufd1 and Npl4; [@B42]) uses the energy of ATP hydrolysis to extract the substrate into the cytosol ([@B46]). We found that overexpressing a catalytically inactive p97 dramatically blocked the degradation of *Akita* proinsulin ([Figure 2, A and B](#F2){ref-type="fig"}), supported by a recent report that chemical inhibition of p97 modestly inhibits *Akita* proinsulin degradation in a manner generally similar to that achieved by chemical inhibition of proteasomes ([@B45]). The notion that p97 at the cytosolic face of the ER membrane facilitates the degradation of ubiquitinated *Akita* proinsulin is further demonstrated by the accumulation of polyubiquitinated *Akita* proinsulin in the presence of the dominant-negative p97 mutant ([Figure 2C](#F2){ref-type="fig"}). Taken together, these findings strongly suggest that p97 mobilizes mutant proinsulin into the cytosol for delivery to proteasomes.

PDI's reductase activity primes *Akita* proinsulin for ERAD
-----------------------------------------------------------

A key and surprising finding of our study involves the role of PDI in initiating retrotranslocation of *Akita* proinsulin for ERAD. Such a conclusion is not unreasonable: whereas PDI does not serve as an oxidase for native proinsulin disulfide bond formation ([@B29]), disulfide isomerase activity may be used to help break nonnative disulfide bonds. Moreover, the development of nonremediable misfolding may "tag" *Akita* proinsulin as a potential ERAD substrate. PDI can operate as a chaperone, facilitating the unfolding of substrates targeted for ERAD before their retrotranslocation ([@B37]; [@B30]), but it is likely that, once selected for ERAD, nonnative (and probably even remaining native) proinsulin disulfide bonds must be reduced so that the unfolded substrate can thread through the retrotranslocon.

In the context of genetic mutation of one of the six evolutionarily conserved proinsulin cysteine residues, the development of nonremediable proinsulin misfolding is guaranteed. An unpaired proinsulin cysteine residue may have the opportunity to attack other cysteines within the same proinsulin molecule or other proteins present in the ER (including other copies of proinsulin, ER oxidoreductases, or others). PDI appears to preferentially interact with the Cys-B19, Cys-A11, and even Cys-A20 of proinsulin ([Figure 3H](#F3){ref-type="fig"} and Supplemental Figure S3), but Cys-B7 (the normal disulfide bonding partner of Cys-A7) is not a preferential site of adduct formation with PDI. Thus *Akita* proinsulin is likely to be involved in a more complex pattern of disulfide mispairing that leads to the generation of PDI adducts. Consistent with this, intermolecular disulfide bonds are observed for *Akita* proinsulin, including both nonnative disulfide-linked proinsulin dimers and trimers and disulfide bonds with other proteins in high- MW complexes ([@B21]; [@B25], [@B24]; [Figure 4](#F4){ref-type="fig"}), and knockdown of PDI causes loss of the dimers and trimers ([Figure 4B](#F4){ref-type="fig"}) while specifically blocking ERAD of *Akita* proinsulin ([Figure 3](#F3){ref-type="fig"}).

Several new and novel observations support the idea that the role of PDI in the ERAD of *Akita* proinsulin is as a reductase. First, trap mutants that can mimic initial PDI reductase activity capture *Akita* proinsulin in disulfide-linked adducts, including adducts that correspond to a direct 1:1 interaction between PDI and *Akita* proinsulin ([Figure 4A](#F4){ref-type="fig"}). Second, expression of these same PDI trap mutants inhibits degradation of *Akita* proinsulin (Supplemental Figure S2C). Third, PDI knockdown causes simple disulfide-bonded *Akita* dimers to be lost ([Figure 4B](#F4){ref-type="fig"}) and to fractionate with high-MW complexes, whereas addition of a chemical reductant mimics the effect of PDI ([Figure 4C](#F4){ref-type="fig"}), strongly suggesting that lack of PDI results in a lack of reducing power for *Akita* proinsulin in the ER. Fourth, purified PDI is capable of reducing *Akita* proinsulin in the high-MW complexes to generate *Akita* dimers and trimers ([Figure 4D](#F4){ref-type="fig"}). Thus our collective findings argue strongly that PDI acts as a reductase to initiate retrotranslocation of *Akita* proinsulin. Because many MIDY mutations involve a loss or gain of a cysteine that promotes formation of nonnative disulfide bonds ([@B24]), the reductase activity of PDI is also likely to promote ERAD of other MIDY mutants. Indeed, the role of PDI in ERAD is far more widespread than for proinsulin alone. We note that the classic components of ERAD, including Sel1L, Hrd1, and p97, are conserved down to yeast; indeed, it is well established that the yeast Sel1L homologue (Hrd3p) recruits lumenal factors for ERAD of substrates that also engage yeast Hrd1 ([@B10]). With this in mind, we note that even in this simple eukaryote, the redox activity of PDI has been shown to be important for ERAD of the mutant CPY\* ([@B14]). Thus it is not surprising that our results for ERAD of *Akita* proinsulin in heterologous HEK 293T cells are also obtained in pancreatic β-cells ([Figure 5](#F5){ref-type="fig"}), as ERAD uses common, ancient, essential pathways.

The pathogenesis of MIDY is attributed to the inability of WT proinsulin to exit the ER, which is a critical step for normal insulin production ([@B24]; [@B40]). Because MIDY proinsulin entraps WT proinsulin in the ER, the less abundant the misfolded proinsulin, the less is the risk of diabetes ([@B18]). In principle, restoration of WT proinsulin exit from the ER, resulting in more WT insulin production, should be possible if efficient disposal of misfolded proinsulin can be achieved. Although there is still much to be learned about the degradation of misfolded proinsulin in the ER, exploiting ERAD may serve as a crucial platform for the development of future therapeutic approaches to combat diabetes caused by ER stress--induced β-cell failure linked to misfolded proinsulin within the ER.

MATERIALS AND METHODS
=====================

Reagents
--------

Antibodies used were as follows: rabbit anti-Myc (Immunology Consultants Laboratories, Portland, OR); mouse anti-VCP (p97), anti-PDI (RL90), and anti-ERp57 (Abcam, Cambridge, MA); rabbit anti-Hrd1 (Proteintech, Chicago, IL); rabbit anti-Hsp90 (H-114; Santa Cruz Biotechnology, Santa Cruz, CA); mouse anti-ubiquitin (Invitrogen, Carlsbad, CA); rabbit anti-FLAG, anti-Sel1L, and mouse and rabbit horseradish peroxidase (HRP) secondary antibodies (Sigma-Aldrich, St. Louis, MO); rabbit anti-Myc (9E10) for immunoprecipitation (IP; K. Verhey, University of Michigan, Ann Arbor, MI). Chemicals were from Sigma-Aldrich except when noted otherwise. Phenylmethylsulfonyl fluoride (PMSF) was from Acros Organics; DMEM, RPM1 1640 medium, and other cell culture reagents were from Life Technologies (Carlsbad, CA). An expression plasmid encoding Myc-epitope--tagged human C(A7)Y *Akita* mutant proinsulin (*Akita*-Myc) was previously described ([@B24]). A second expression plasmid encoding Myc-tagged human C(A7)Y proinsulin was constructed in which all five remaining Cys residues were mutated to Ser residues; this kind of construct, previously referred to as proinsulin-DelCys ([@B23]), is also known here as ΔCys-Myc. Six related expression plasmids encoding Myc-tagged human proinsulin were constructed in which five Cys residues were mutated to Ser; each construct retains only one Cys residue, and they are referred to as Keep B7, Keep B19, Keep A6, Keep A7, Keep A11, and Keep A20, respectively. Purification of His-tagged PDI from bacteria was as previously described ([@B11]). Human PDI trap mutants were gifts from T. Rapoport (Harvard University, Cambridge, MA). The INS-1 832/13 β-cell line was a generous gift from Christopher Newgard (University of Texas Southwestern, Dallas, TX).

Cell culture, plasmid transfection, cycloheximide chase, immunoprecipitation, and immunoblotting
------------------------------------------------------------------------------------------------

Rat INS-1 832/13 or human HEK 293T cells were cultured at 37°C in a humid incubator (5% CO~2~). Cells were seeded on six-well plates 1 d before transfection of 1--3 μg of plasmid DNA using home-made polyethylenimine (PEI) or Lipofectamine 2000 (Invitrogen). At 4 h posttransfection, cells were treated with cycloheximide (100 μg/ml) and chased for 0, 2, 4, and 6 h. In experiments using ΔCys-Myc or single-Cys Keep mutants, cells were treated with MG132 (10 μM) for 3 h before cell lysis. Cells were harvested in phosphate-buffered saline (PBS) containing 10 mM *N*-ethylmaleimide (NEM). For IP, cells were lysed in 400 μl of RIPA buffer (Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 1% sodium dexoycholate, 0.1% SDS) supplemented with 10 mM NEM and 1 mM PMSF; in [Figure 3H](#F3){ref-type="fig"}, the modified RIPA buffer contained 0.25% SDS. Cells were incubated on ice for 10 min and centrifuged, and the resulting whole-cell extract (WCE) was incubated with antibody (1:200) at 4°C for 24 h, followed by 2 h of incubation with precleared protein A/G-agarose beads at 4°C. Beads were washed three times and boiled in SDS sample buffer with or without 100 mM DTT. For immunoblot analyses, cells were lysed in 100 μl of RIPA buffer to generate WCE, which was boiled in SDS sample buffer with 100 mM DTT. Then samples were resolved on 8--15% SDS--PAGE gels, transferred to nitrocellulose, and blotted with specific primary and HRP-conjugated secondary (1:2000) antibodies according to manufacturer's protocols (Sigma-Aldrich).

siRNA knockdown of Hrd1, Sel1L, and PDI
---------------------------------------

siRNA was transfected into cells using RNAiMAX (Invitrogen), and cells were chased and harvested 48--72 h posttreatment. The sequences of the siRNAs are as follows: Dharmacon human Hrd1, 5′-GGAGACUGCCACUACAGUUGUUU-3′, at 10 nM for 48-h knockdown; Dharmacon human Sel1L, 5′-GAAACAAACAUUCGAGAUAUU-3′, at 25 nM for 48-h knockdown; and human PDI, 5′-CAACUUUGAAGGGGAGGUCTT-3′, and rat PDI, 5′-GCGCAUACUUGAGUUCUUUTT-3′, at 75 nM for 72-h knockdown.

siRNA-resistant PDI construct
-----------------------------

siRNA-resistant WT PDI was generated with KOD Hot Start DNA polymerase (EMD Chemicals, Billerica, MA) from mouse WT PDI according to the manufacturer's protocol. The sequences of forward and reverse primers are as follows: forward, 5′-GCAGCTAGCCCCCATTTGGGACAAGCTCGGCGAAACCTACAAGGATCATGAGAATATC-3′; and reverse, 5′-GATATTCTCATGATCCTT­GTAGGTTTCGCCGAGCTTG TCCCAAATGGGGGCTAGCTGC-3′. The mutated siRNA-resistant PDI construct was confirmed by sequencing. A 2-μg amount of siRNA-resistant PDI plasmid was transfected into HEK 293T cells with PEI 24 h posttransfection of the PDI siRNA.

Sucrose cushion sedimentation
-----------------------------

Cells transfected with scrambled or PDI siRNA were lysed in RIPA buffer to generate a WCE as described. WCE was centrifuged at 50,000 rpm at 4°C for 20 min using a TLA 100 rotor (Beckman, Brea, CA). Half of the resulting supernatant (50 μl) was treated or not with DTT (100 mM) for 30 min on ice, layered over an equal volume of a 20% sucrose solution, and centrifuged at 75,000 rpm at 4°C for 30 min using the same rotor. Top (50 μl) and bottom (50 μl) fractions were separated and subjected to immunoblot analyses.

In vitro PDI reduction assay
----------------------------

PDI was expressed in *Escherichia coli* strain BL21-Pro and purified as previously described ([@B11]). Purified PDI was aliquoted and stored at −80°C. *Akita-Myc* was expressed in PDI-depleted HEK 293T cells for 24 h, followed by cell lysis (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid \[HEPES\], 150 mM NaCl, 1% Triton X-100, 10 mM NEM, and 1 mM PMSF) and overnight immunoprecipitation as described. After three washes, *Akita*-Myc was eluted in 20 μl of a 0.5% SDS buffer at room temperature for 30 min, dialyzed, and diluted to 200 μl in a buffer containing 50 mM HEPES and 150 mM NaCl. Isolated *Akita*-Myc was incubated in the presence of 1 mM GSH and 1 mM GSSG with either PDI or PDI alkylated with 25 mM IAA, and the reaction was continued at 37°C for 30 min. Samples were separated on a nonreducing SDS--PAGE and subjected to immunoblot analysis.
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CHX
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:   endoplasmic reticulum

ERAD

:   ER-associated degradation
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:   green fluorescent protein

GSH
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GSSG

:   oxidized glutathione

IAA

:   iodoacetamide
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:   iodoacetamide-treated protein disulfide isomerase
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:   mutant *INS* gene--induced diabetes of youth
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:   protein disulfide isomerase
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:   superfolder green fluorescent protein
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:   small interfering RNA

Ub

:   ubiquitin
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